An Open-label, 8-Week Study of Safety and Efficacy for Adjunctive Pimavanserin Treatment in Adults With Parkinson's Disease and Inadequately Controlled Depression

Trial Profile

An Open-label, 8-Week Study of Safety and Efficacy for Adjunctive Pimavanserin Treatment in Adults With Parkinson's Disease and Inadequately Controlled Depression

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 05 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top